Cyprus vs United Arab Emirates: Statin use vs. average non-HDL cholesterol levels
Cyprus
3.5
in 2018
United Arab Emirates
3.5
in 2018
Cyprus rank
52nd
United Arab Emirates rank
52nd
Statin use vs. average non-HDL cholesterol levels over time
- Cyprus
- United Arab Emirates
How they compare
Cyprus currently reports 3.5 against 3.5 in United Arab Emirates, a difference of 0.
The two have swapped places 7 times across 39 shared years of data; in 1980 it was Cyprus ahead.
Cyprus ranks 52nd and United Arab Emirates ranks 52nd of 191 countries.
Cyprus has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Cyprus | United Arab Emirates | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 4.2 | 3.9 | 0.3 | Cyprus |
| 1990s | 4.04 | 3.87 | 0.17 | Cyprus |
| 2000s | 3.79 | 3.75 | 0.04 | Cyprus |
| 2010s | 3.62 | 3.56 | 0.0667 | Cyprus |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Cyprus or United Arab Emirates?
- Cyprus, at 3.5 against 3.5 in United Arab Emirates as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Cyprus and United Arab Emirates?
- 0, with Cyprus ahead.
- How many years of comparable data are there for Cyprus and United Arab Emirates?
- 39 years are reported by both, from 1980 to 2018.
- How do Cyprus and United Arab Emirates rank globally for statin use vs. average non-hdl cholesterol levels?
- Cyprus ranks 52nd and United Arab Emirates ranks 52nd of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.